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Abstract
Background: Preventing injection drug use among vulnerable youth is critical for reducing serious drug-related
harms. Addiction treatment is one evidence-based intervention to decrease problematic substance use; however,
youth frequently report being unable to access treatment services and the impact of this on drug use trajectories
remains largely unexplored. This study examines the relationship between being unable to access addiction
treatment and injection initiation among street-involved youth.
Methods: Data were derived from the At-Risk Youth Study (ARYS), a prospective cohort of street-involved youth aged
14–26 who use illicit drugs, from September 2005 to May 2014. An extended Cox model with time-dependent variables
was used to identify factors independently associated with injection initiation.
Results: Among 462 participants who were injection naïve at baseline, 97 (21 %) initiated injection drug use over study
follow-up and 129 (28 %) reported trying but being unable to access addiction treatment in the previous 6 months at
some point during the study period. The most frequently reported reason for being unable to access treatment was
being put on a wait list. In a multivariable Cox regression analysis, being unable to access addiction treatment remained
independently associated with a more rapid rate of injection initiation (Adjusted Hazard Ratio =2.02; 95 % Confidence
Interval: 1.12–3.62), after adjusting for potential confounders.
Conclusion: Inability to access addiction treatment was common among our sample and associated with injection
initiation. Findings highlight the need for easily accessible, evidence-based addiction treatment for high-risk youth as
a means to prevent injection initiation and subsequent serious drug-related harms.
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Findings
Preventing vulnerable youth from initiating injection
drug use is critical for reducing drug-related morbidity
and mortality [1–4]. There are a number of features of
young drug injectors that highlight the urgency of inter-
vening early in their drug use trajectories to prevent the
transition to injection drug use [5]. For instance, prior
research among street-involved youth indicates that once
youth initiate injection drug use, the majority rapidly
become established injectors [6]. Young new injection
initiators are also more prone to engage in risky drug
use practices that put them at higher risk of drug over-
dose and infectious disease transmission [3, 4, 7–9].
Structural level influences, such as homelessness and
unemployment [10–12], alongside individual level fac-
tors including childhood trauma, and specific drug use
patterns [13, 14], have been recognized as factors that fa-
cilitate transitions into injection drug use among vulner-
able youth. While these findings suggest that injection
prevention efforts should be directed to the areas of
housing, employment, and childhood trauma prevention
and recovery, addiction treatment may provide add-
itional opportunities to reduce injection initiation. It has
long been established that addiction treatment is one of
the most cost-effective interventions to reduce problem-
atic substance use [15, 16]. However, prior studies
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indicate that many vulnerable individuals are unable to
access addiction treatment [17–20]. To determine the
role that barriers to accessing addiction treatment may
play in influencing drug use trajectories, we examined
whether inability to access addiction treatment was asso-
ciated with injection initiation among a cohort of street-
involved youth.
Methods
Data for this study was obtained from the At-Risk
Youth Study (ARYS), which is an open prospective
cohort of street-involved youth in Vancouver, Canada
that has been described in detail previously [21]. In
brief, study recruitment is open and undertaken
using snowball sampling and extensive street-based
outreach methods. To be eligible, participants at re-
cruitment must be age 14–26 years, have used illicit
drugs in the past 30 days, and provide written
informed consent. At baseline and on a semi-annual
basis, participants complete an interviewer-administered
questionnaire that elicits information related to drug use
and contact with health and social services. At each study
visit participants are provided with a stipend ($30
Canadian currency) for their time. The study has
been approved by the University of British Columbia’s
Research Ethics Board.
The study period for this analysis was September 2005
to May 2014. To examine the potential relationship be-
tween initiation into injection drug use and inability to
access addiction treatment, all participants who had
never injected drugs at baseline and had completed at
least one follow-up visit during the study period were in-
cluded in the present analysis. The primary outcome of
interest was injection initiation which was defined as the
midpoint between the last report of remaining injection
naïve and the first report of having used a needle to
chip, fix or muscle drugs. For descriptive purposes we
also assessed the median number of years between initi-
ation of non-injection “hard” drug use (defined as use of
heroin, cocaine, crack, or crystal methamphetamine) and
initiation of injection drug use. These estimates were
based on the reported age of first non-injection “hard”
drug use, and age of participants at the midpoint be-
tween the last report of remaining injection naïve and
the first report of having used a needle to chip, fix, or
muscle drugs. The primary explanatory variable of inter-
est was being unable to access addiction treatment de-
fined as responding affirmatively to the question: "In the
past 6 months, have you tried to access any treatment
program but were unable?" Participants were also asked
to specify the types of addiction treatment they had diffi-
culty accessing (e.g., detox, recovery house, treatment
center, counselor, other), as well as the main reason they
were unable to access the program (waiting lists,
behavioral issues, rejection from program, logistics such
as hours of optional, location, paperwork etc.).
To determine whether there was a significant relation-
ship between our outcome of interest and our primary
explanatory variable we a priori selected a range of sec-
ondary explanatory variables we hypothesized might be
associated with both injection initiation and being un-
able to access addiction treatment. Secondary explana-
tory factors included: number of years since initiated
“hard” drug use defined as use of cocaine, crack, heroin,
or crystal methamphetamine (per additional year); gen-
der (female vs. male); ethnicity (Caucasian vs. other);
non-injection cocaine use (yes vs. no); crack smoking
(yes vs. no); non-injection crystal methamphetamine use
(yes vs. no); and non-injection heroin use (yes vs. no).
All drug use variables including being unable to access
addiction treatment refer to circumstances and behav-
iors over the previous 6 months and were treated as
time-updated covariates on the basis of semi annual
follow-up data. In addition, to protect against reverse
causation whereby reported behaviors were a conse-
quence of drug injecting, all drug use variables including
being unable to access addiction treatment were lagged
to the previous available observation [10, 11].
To assess the relationship between being unable to ac-
cess addiction treatment and injection initiation, as a
first step we calculated the incidence density of injection
initiation using a Poisson model. Then, using an ex-
tended Cox model with time-dependent variables, we es-
timated the unadjusted relative hazards and 95 %
confidence intervals for factors associated with injection
initiation [22]. To fit our multivariable Cox model, we
ran a fixed multivariable model where all variables of
interest were included into a single model. All statistical
analyses were performed using SAS software version 9.3
(SAS, Cary, NC, USA). All tests of significance were
two-sided.
Results
Overall, 1157 street-involved youth were recruited into
the ARYS cohort during the study period. At enrolment
659 (57 %) youth had never injected drugs. Among this
group, during the study period, the average yearly loss to
follow-up rate was 3.15 %. At the time the analysis was
conducted, 462 (70 %) participants completed at least
one study follow-up to assess for injection initiation and
were therefore included in the analysis. There were no
significant differences with respect to gender (Chi-square
p-value =0.943; degrees of freedom [df] =1) or ethnicity
(Chi-square p-value =0.117; df =1) between the 462 youth
who represented the eligible study population and the 197
injecting naïve youth who were ineligible because they ei-
ther did not have a follow up visit at the time the analysis
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was conducted or were not enrolled in the cohort long
enough to be due for a study follow-up.
Among the sample of 462 youth included in the study,
142 (31 %) were female and the median age was
21.5 years (interquartile range [IQR] = 19.6–23.2). The
median number of study visits was 4 (IQR = 2–6), the
median time between study visits was 6.2 (IQR: 5.7–8.1)
months, and the median follow up time per participant
was 22.4 (IQR = 11.9–43.2) months. Baseline characteris-
tics of the study sample are presented in Table 1. Over
study follow-up, 97 (21 %) injection initiation events
were observed for an incidence density of 8.6 cases per
100 person years [95 % Confidence Interval (CI): 7.0–
10.6]. The median time to injection initiation from study
enrolment was 11.2 months (IQR: 3.9–23.9), and the
median number of years between initiation of non-
injection “hard” drug use (defined as use of heroin,
cocaine, crack, or crystal methamphetamine) and initi-
ation of injection drug use was 7.1 (IQR = 4.6–9.5).
At some point during the study period 129 (28 %)
youth reported being unable to access addiction treat-
ment. In total, 183 study observations included a report
of being unable to access addiction treatment. Among
these study observations, the most common type of ad-
diction treatment that participants reported being unable
to access was detox services (n = 76, 41 %), followed by
treatment centers (n = 65, 35 %), recovery houses (n =
20, 10 %), and counselors (n = 8, 4 %). The main reason
participants reported being unable to access addition
treatment was waiting lists (n = 118, 66 %), followed by
logistical issues such as hours of optional, location, re-
quired paperwork etc. (n = 32, 18 %). Being rejected from
the program for an unspecified reason (n = 16, 9 %), and
having behavioral issues (n = 10, 6 %) were two other
Table 1 Baseline characteristics and Cox regression analysis for factors associated with injection initiation among street-involved
youth (n = 462)
Characteristic Baseline Characteristics Bivariable and Multivariable Cox Regression Analysis
Injection Initiation Unadjusted HRa p-value Adjusted HR
(95 % CI)
p-
valuefYes (n = 97) n (%) No (n = 365) n (%) (95 % CI)b
Unable to access addiction treatment d,e
Yes 15 (15.5) 33 (9.0) 2.19 (1.27–3.78) 0.005 2.02 (1.12–3.62) 0.019
No 80 (82.5) 324 (88.8)
Years since initiated hard drug use (HR per additional year)
Median 5.4 5.4 1.00 (0.94–1.07) 0.893 0.99 (0.92–1.06) 0.714
IQR (3.7–7.8) (3.1–7.9)
Caucasian Ethnicity
Yes 68 (70.1) 219 (60.0) 1.50 (0.97–2.31) 0.069 1.40 (0.88–2.21) 0.152
No 29 (29.9) 146 (40.0)
Female Gender
Yes 28 (28.9) 114 (31.2) 0.96 (0.62–1.50) 0.872 1.06 (0.68–1.65) 0.805
No 69 (71.1) 251 (68.8)
Heroin Usec,d,e
Yes 24 (24.7) 52 (14.2) 2.12 (1.34–3.36) 0.001 1.48 (0.86–2.55) 0.157
No 70 (72.2) 307 (84.1)
Cocaine Usec,d,e
Yes 43 (44.3) 186 (51.0) 1.17 (0.77–1.78) 0.449 1.06 (0.69–1.64) 0.782
No 52 (53.6) 176 (48.2)
Crack Smokingd,e
Yes 68 (70.1) 190 (52.1) 1.71 (1.11–2.63) 0.015 1.23 (0.76–1.97) 0.402
No 27 (27.8) 171 (46.8)
Crystal Meth Usec,d,e
Yes 51 (52.6) 122 (33.4) 2.31 (1.53–3.47) <0.001 2.00 (1.32–3.04) 0.001
No 43 (44.3) 238 (65.2)
Not all cells add up to 462 as participants may choose not to answer sensitive questions
aHR hazard ratio; bCI confidence interval
cdenotes non-injection use; ddenotes activities in the 6 months prior to follow-up interview; erefers to the activities lagged to the pervious available study follow-up;
fp-values based on Wald test
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common barriers. Note, out of the 183 observations that
included a report of being unable to access addiction
treatment, 10 observations did not specify the type of
treatment that the participant was unable to access, 162
observations indicated one type of treatment, and 11 ob-
servations indicated 2 types of treatment. Similarly, 11
observations did not specify a reason the participant was
unable to access treatment, 164 observations indicated
one reason, and 8 observations indicated 2 reasons.
Table 1 shows the unadjusted and adjusted relative
hazards of injection initiation. Being unable to access
addiction treatment was significantly associated with
injection initiation in both bivariable [hazard ratio =2.19,
95 % CI: 1.27–3.78] and multivariable Cox regression ana-
lyses [adjusted hazard ratio =2.02, 95 % CI: 1.12–3.62].
Discussion
Among our sample of youth, 28 % sought but were un-
able to access addiction treatment at some point during
the study period. Youth who were unable to access ad-
diction treatment were over two times more likely to
subsequently initiate injection drug use, highlighting a
critical missed opportunity to intervene to prevent injec-
tion initiation among high-risk youth. These findings are
consistent with prior studies indicating that inability to
access and engage with key health and social services,
such as addiction treatment, housing, and employment
negatively influences drug use behaviors and trajectories
among vulnerable populations [10–12, 19, 23]. Prior
cross-sectional analyses also found that contact with
addiction treatment significantly delayed injection initi-
ation among heroin users in the United States, highlight-
ing the protective benefits of addiction treatment [24].
Given the importance of intervening early in youths’
drug use trajectories to prevent injection initiation, our
findings indicate that addressing deficiencies in youth
addiction treatment, particularly with respect to waiting
lists and logistical issues, should be a top priority. Numer-
ous barriers to accessing addiction treatment have been
identified in the literature and include: limited availability
and insufficient use of evidence-based medication-assisted
therapies; long wait times; lack of adequately trained pro-
viders; age restrictions; limited hours of operation; dis-
crimination; and stigma, among others [18, 19, 25–31].
Our study has limitations. First, as with other studies
of street-involved youth, the ARYS cohort is not a ran-
dom sample and therefore these findings may not
generalize to other populations. Second, this study is
based on self-reported information and is susceptible to
recall bias and socially desirable responding. We antici-
pate that any response bias would likely underestimate
the prevalence of risk behaviors and therefore bias our
results towards the null.
In summary, we found that inability to access addic-
tion treatment predicted injection initiation among
street-involved youth. Facilitating engagement with ad-
diction treatment by reducing wait lists and increasing
the availability of low-threshold evidence-based treat-
ments offer important opportunities to engage with
vulnerable youth and potentially prevent them from
transitioning to injection drug use.
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